Zydus Lifesciences Limited — Updates, 10-06-2025: Press Release

Zydus has announced a board meeting to review the financial results for the quarter and half-year. The company received the EIR report from the USFDA for its Dabhasa API manufacturing facility inspection, classified as Voluntary Action Indicated (VAI), with the inspection now closed. This reflects ongoing regulatory compliance with no immediate financial impact.